Switching HIV Treatment After Cabotegravir/Rilpivirine Failure
Part of Immune system & allergy, Infections clinical trials.
This study tests whether switching to a new three-drug HIV combination (bictegravir, emtricitabine, and tenofovir alafenamide) works safely and effectively for people whose HIV became resistant to cabotegravir/rilpivirine injections. Researchers will compare outcomes in people who make this switch.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have HIV and your virus became resistant to cabotegravir/rilpivirine (CAB/RPV) injections within the last 3 years
- Your HIV has not developed resistance to two of the drugs in the new combination: emtricitabine (FTC) and tenofovir alafenamide (TAF)
- You are willing to switch from injections to the new tablet-based treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two HIV medications (DTG/3TC and BIC/TAF/FTC) to see which works better and is safer for people who have never taken HIV treatment before. It may help you find a once-daily pill that controls the virus and has fewer side effects.
This study tests a newer HIV medication, B/F/TAF, as a first-line treatment. It compares B/F/TAF with older combinations (TDF+3TC+EFV or DTG/3TC) to see how well it works for people who have never taken HIV meds.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
This study looks at switching people with HIV from daily or regular oral medicine to long-acting injections (cabotegravir plus rilpivirine). It may help those who are well-controlled on current therapy who prefer injections and can safely take this combination.
This study tests whether switching to a simpler, two-drug HIV pill (dolutegravir/lamivudine) is as safe and effective as staying on a three-drug regimen. It is for people whose HIV is already well-controlled and who are currently taking Biktarvy or Triumeq.
This trial tests if switching to a two-drug combination of dolutegravir and lamivudine is safe and effective for transgender women who already have undetectable HIV levels on a three-drug regimen. It aims to simplify treatment and reduce side effects.
Hear when a new HIV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.